VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q50058486 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233149.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q50058486‏
024 ‎‡a 0000-0002-6931-1355‏ ‎‡2 orcid‏
024 ‎‡a 54397531500‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q50058486‏
100 0 ‎‡a Marina Pinheiro‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Marina Pinheiro‏ ‎‡c researcher (ORCID 0000-0002-6931-1355)‏ ‎‡9 en‏
400 0 ‎‡a Marina Pinheiro‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's A 17-mer Membrane-Active MSI-78 Derivative with Improved Selectivity toward Bacterial Cells.‏
670 ‎‡a Author's Acylation of the S4-PV cell-penetrating peptide as a means of enhancing its capacity to mediate nucleic acid delivery: Relevance of peptide/lipid interactions‏
670 ‎‡a Author's Antibiotic interactions using liposomes as model lipid membranes‏
670 ‎‡a Author's Antimicrobial properties of membrane-active dodecapeptides derived from MSI-78.‏
670 ‎‡a Author's Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline‏
670 ‎‡a Author's Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells‏
670 ‎‡a Author's Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.‏
670 ‎‡a Author's Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.‏
670 ‎‡a Author's Drug-membrane interaction studies applied to N'-acetyl-rifabutin.‏
670 ‎‡a Author's Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study.‏
670 ‎‡a Author's Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane‏
670 ‎‡a Author's Effects of novel triple-stage antimalarial ionic liquids on lipid membrane models‏
670 ‎‡a Author's EGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriers‏
670 ‎‡a Author's EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways‏
670 ‎‡a Author's Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy‏
670 ‎‡a Author's Evaluation of the effect of rifampicin on the biophysical properties of the membranes: Significance for therapeutic and side effects‏
670 ‎‡a Author's Evaluation of the Structure-Activity Relationship of Rifabutin and Analogs: A Drug-Membrane Study‏
670 ‎‡a Author's Folate-targeted nanostructured lipid carriers for enhanced oral delivery of epigallocatechin-3-gallate‏
670 ‎‡a Author's In Vitro Assessment of NSAIDs-Membrane Interactions: Significance for Pharmacological Actions‏
670 ‎‡a Author's Insights about α-tocopherol and Trolox interaction with phosphatidylcholine monolayers under peroxidation conditions through Brewster angle microscopy‏
670 ‎‡a Author's Insights into the Membranolytic Activity of Antimalarial Drug-Cell Penetrating Peptide Conjugates‏
670 ‎‡a Author's Interactions of isoniazid with membrane models: Implications for drug mechanism of action‏
670 ‎‡a Author's Interactions of N′-acetyl-rifabutin and N′-butanoyl-rifabutin with lipid bilayers: A synchrotron X-ray study‏
670 ‎‡a Author's Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: A biophysical approach to disease‏
670 ‎‡a Author's Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages‏
670 ‎‡a Author's Molecular interaction of Rifabutin on model lung surfactant monolayers.‏
670 ‎‡a Author's Molecular interactions of rifabutin with membrane under acidic conditions.‏
670 ‎‡a Author's Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis‏
670 ‎‡a Author's Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy‏
670 ‎‡a Author's Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment‏
670 ‎‡a Author's The formulation of nanomedicines for treating tuberculosis‏
670 ‎‡a Author's The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs)‏
670 ‎‡a Author's Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems‏
670 ‎‡a Author's Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model‏
909 ‎‡a (scopus) 54397531500‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000269311355‏ ‎‡9 1‏
919 ‎‡a epigallocatechingallatenanodeliverysystemsforcancertherapy‏ ‎‡A Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy‏ ‎‡9 1‏
919 ‎‡a egcgintestinalabsorptionandoralbioavailabilityenhancementusingfolicacidfunctionalizednanostructuredlipidcarriers‏ ‎‡A EGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriers‏ ‎‡9 1‏
919 ‎‡a effectsofnoveltriplestageantimalarialionicliquidsonlipidmembranemodels‏ ‎‡A Effects of novel triple-stage antimalarial ionic liquids on lipid membrane models‏ ‎‡9 1‏
919 ‎‡a effectsofanovelantimycobacterialcompoundonthebiophysicalpropertiesofapulmonarysurfactantmodelmembrane‏ ‎‡A Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane‏ ‎‡9 1‏
919 ‎‡a effectofthealkylgroupinthepiperazinensubstitutiononthetherapeuticactionofrifamycinsadrugmembraneinteractionstudy‏ ‎‡A Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study.‏ ‎‡9 1‏
919 ‎‡a drugmembraneinteractionstudiesappliedtonacetylrifabutin‏ ‎‡A Drug-membrane interaction studies applied to N'-acetyl-rifabutin.‏ ‎‡9 1‏
919 ‎‡a designofananostructuredlipidcarrierintendedtoimprovethetreatmentoftuberculosis‏ ‎‡A Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.‏ ‎‡9 1‏
919 ‎‡a designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation‏ ‎‡A Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.‏ ‎‡9 1‏
919 ‎‡a designandstatisticalmodelingofmannosedecorateddapsonecontainingnanoparticlesasastrategyoftargetingintestinal1000cells‏ ‎‡A Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells‏ ‎‡9 1‏
919 ‎‡a antituberculosisdruginteractionswithmembranesabiophysicalapproachappliedtobedaquiline‏ ‎‡A Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline‏ ‎‡9 1‏
919 ‎‡a antimicrobialpropertiesofmembraneactivedodecapeptidesderivedfrommsi78‏ ‎‡A Antimicrobial properties of membrane-active dodecapeptides derived from MSI-78.‏ ‎‡9 1‏
919 ‎‡a antibioticinteractionsusingliposomesasmodellipidmembranes‏ ‎‡A Antibiotic interactions using liposomes as model lipid membranes‏ ‎‡9 1‏
919 ‎‡a acylationofthes4pvcellpenetratingpeptideasameansofenhancingitscapacitytomediatenucleicaciddeliveryrelevanceofpeptidelipidinteractions‏ ‎‡A Acylation of the S4-PV cell-penetrating peptide as a means of enhancing its capacity to mediate nucleic acid delivery: Relevance of peptide/lipid interactions‏ ‎‡9 1‏
919 ‎‡a 17mermembraneactivemsi78derivativewithimprovedselectivitytowardbacterialcells‏ ‎‡A A 17-mer Membrane-Active MSI-78 Derivative with Improved Selectivity toward Bacterial Cells.‏ ‎‡9 1‏
919 ‎‡a egcgmediatedtargetingofderegulatedsignalingpathwaysandnoncodingrnasindifferentcancersfocusonjakstatwntβcatenintgfsmadnotchshhgliandtrailmediatedsignalingpathways‏ ‎‡A EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways‏ ‎‡9 1‏
919 ‎‡a treatmentoffrancisellainfectionsviaplgaandlipidbasednanoparticledeliveryofantibioticsinazebrafishmodel‏ ‎‡A Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model‏ ‎‡9 1‏
919 ‎‡a therapeuticpotentialofepigallocatechingallatenanodeliverysystems‏ ‎‡A Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems‏ ‎‡9 1‏
919 ‎‡a interleukin1il1superfamilycytokinesandtheirsinglenucleotidepolymorphismssnps‏ ‎‡A The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs)‏ ‎‡9 1‏
919 ‎‡a formulationofnanomedicinesfortreatingtuberculosis‏ ‎‡A The formulation of nanomedicines for treating tuberculosis‏ ‎‡9 1‏
919 ‎‡a targetedmacrophagesdeliveryofrifampicinloadedlipidnanoparticlestoimprovetuberculosistreatment‏ ‎‡A Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment‏ ‎‡9 1‏
919 ‎‡a optimizationofrifapentineloadedlipidnanoparticlesusingaqualitybydesignstrategy‏ ‎‡A Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy‏ ‎‡9 1‏
919 ‎‡a mucoadhesivechitosancoatedsolidlipidnanoparticlesforbettermanagementoftuberculosis‏ ‎‡A Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis‏ ‎‡9 1‏
919 ‎‡a molecularinteractionsofrifabutinwithmembraneunderacidicconditions‏ ‎‡A Molecular interactions of rifabutin with membrane under acidic conditions.‏ ‎‡9 1‏
919 ‎‡a molecularinteractionofrifabutinonmodellungsurfactantmonolayers‏ ‎‡A Molecular interaction of Rifabutin on model lung surfactant monolayers.‏ ‎‡9 1‏
919 ‎‡a mannosylatedsolidlipidnanoparticlesfortheselectivedeliveryofrifampicintomacrophages‏ ‎‡A Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages‏ ‎‡9 1‏
919 ‎‡a interplayofmycolicacidsantimycobacterialcompoundsandpulmonarysurfactantmembraneabiophysicalapproachtodisease‏ ‎‡A Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: A biophysical approach to disease‏ ‎‡9 1‏
919 ‎‡a interactionsofnacetylrifabutinandnbutanoylrifabutinwithlipidbilayersasynchrotron10raystudy‏ ‎‡A Interactions of N′-acetyl-rifabutin and N′-butanoyl-rifabutin with lipid bilayers: A synchrotron X-ray study‏ ‎‡9 1‏
919 ‎‡a interactionsofisoniazidwithmembranemodelsimplicationsfordrugmechanismofaction‏ ‎‡A Interactions of isoniazid with membrane models: Implications for drug mechanism of action‏ ‎‡9 1‏
919 ‎‡a insightsintothemembranolyticactivityofantimalarialdrugcellpenetratingpeptideconjugates‏ ‎‡A Insights into the Membranolytic Activity of Antimalarial Drug-Cell Penetrating Peptide Conjugates‏ ‎‡9 1‏
919 ‎‡a insightsaboutαtocopherolandtroloxinteractionwithphosphatidylcholinemonolayersunderperoxidationconditionsthroughbrewsteranglemicroscopy‏ ‎‡A Insights about α-tocopherol and Trolox interaction with phosphatidylcholine monolayers under peroxidation conditions through Brewster angle microscopy‏ ‎‡9 1‏
919 ‎‡a invitroassessmentofnsaidsmembraneinteractionssignificanceforpharmacologicalactions‏ ‎‡A In Vitro Assessment of NSAIDs-Membrane Interactions: Significance for Pharmacological Actions‏ ‎‡9 1‏
919 ‎‡a folatetargetednanostructuredlipidcarriersforenhancedoraldeliveryofepigallocatechin3gallate‏ ‎‡A Folate-targeted nanostructured lipid carriers for enhanced oral delivery of epigallocatechin-3-gallate‏ ‎‡9 1‏
919 ‎‡a evaluationofthestructureactivityrelationshipofrifabutinandanalogsadrugmembranestudy‏ ‎‡A Evaluation of the Structure-Activity Relationship of Rifabutin and Analogs: A Drug-Membrane Study‏ ‎‡9 1‏
919 ‎‡a evaluationoftheeffectofrifampicinonthebiophysicalpropertiesofthemembranessignificancefortherapeuticandsideeffects‏ ‎‡A Evaluation of the effect of rifampicin on the biophysical properties of the membranes: Significance for therapeutic and side effects‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 DNB|1051996422‏
996 ‎‡2 SUDOC|02982608X‏
996 ‎‡2 LC|no2004061291‏
996 ‎‡2 ISNI|0000000070916365‏
996 ‎‡2 LC|n 92020990‏
996 ‎‡2 ISNI|0000000069808009‏
996 ‎‡2 ISNI|0000000070499792‏
996 ‎‡2 PTBNP|196769‏
996 ‎‡2 LC|n 78071810‏
996 ‎‡2 BLBNB|000338571‏
996 ‎‡2 BLBNB|000510844‏
996 ‎‡2 BLBNB|000263006‏
996 ‎‡2 ISNI|0000000001313851‏
996 ‎‡2 ISNI|0000000048229630‏
996 ‎‡2 PTBNP|794702‏
996 ‎‡2 SUDOC|168612364‏
996 ‎‡2 BNCHL|10000000000000000105356‏
996 ‎‡2 BNF|12137072‏
996 ‎‡2 LC|n 2015235919‏
996 ‎‡2 PTBNP|38583‏
996 ‎‡2 BLBNB|000370066‏
996 ‎‡2 LC|n 78031377‏
996 ‎‡2 LC|no2011115110‏
996 ‎‡2 DNB|115723237X‏
996 ‎‡2 PTBNP|1607244‏
996 ‎‡2 BLBNB|000303349‏
996 ‎‡2 DNB|107470259X‏
996 ‎‡2 PTBNP|1466201‏
996 ‎‡2 LC|no2007158375‏
996 ‎‡2 PTBNP|1043210‏
996 ‎‡2 LC|no2006092387‏
996 ‎‡2 PLWABN|9810696413305606‏
996 ‎‡2 PTBNP|225697‏
996 ‎‡2 BLBNB|000227775‏
996 ‎‡2 ISNI|0000000068493658‏
996 ‎‡2 SUDOC|08012433X‏
996 ‎‡2 PTBNP|181233‏
996 ‎‡2 BLBNB|000352251‏
996 ‎‡2 BNF|11988632‏
996 ‎‡2 PTBNP|244693‏
996 ‎‡2 DNB|1056799978‏
996 ‎‡2 ISNI|0000000070607570‏
996 ‎‡2 LC|n 88609184‏
996 ‎‡2 ISNI|0000000070703730‏
996 ‎‡2 DNB|139356606‏
996 ‎‡2 LC|no2002015375‏
996 ‎‡2 ISNI|0000000067066531‏
996 ‎‡2 BLBNB|000322401‏
996 ‎‡2 BLBNB|000322387‏
996 ‎‡2 ISNI|0000000112073598‏
996 ‎‡2 DNB|1061224511‏
996 ‎‡2 PTBNP|1765034‏
996 ‎‡2 ISNI|0000000046181143‏
996 ‎‡2 LC|no2006052761‏
996 ‎‡2 BLBNB|000199212‏
996 ‎‡2 J9U|987007516706605171‏
996 ‎‡2 LC|no2002053675‏
996 ‎‡2 NSK|000551414‏
996 ‎‡2 PTBNP|1174954‏
996 ‎‡2 SUDOC|165713429‏
996 ‎‡2 ISNI|0000000070121108‏
996 ‎‡2 B2Q|0000298690‏
996 ‎‡2 PTBNP|1545398‏
996 ‎‡2 PTBNP|1670365‏
996 ‎‡2 PTBNP|1213420‏
996 ‎‡2 SUDOC|117323853‏
996 ‎‡2 BNF|14612481‏
996 ‎‡2 LC|nb 99158197‏
996 ‎‡2 PTBNP|1588498‏
996 ‎‡2 LC|n 85361674‏
996 ‎‡2 ISNI|0000000068803441‏
996 ‎‡2 SUDOC|111172314‏
996 ‎‡2 DNB|1336748419‏
996 ‎‡2 PTBNP|89650‏
996 ‎‡2 SUDOC|033124868‏
996 ‎‡2 ISNI|0000000070430779‏
996 ‎‡2 ISNI|0000000029960882‏
996 ‎‡2 LC|n 2015238403‏
996 ‎‡2 ISNI|0000000069415790‏
996 ‎‡2 LC|n 2006067986‏
996 ‎‡2 LC|n 85343182‏
996 ‎‡2 BLBNB|000494093‏
996 ‎‡2 ISNI|0000000076248628‏
996 ‎‡2 BLBNB|000462457‏
996 ‎‡2 PTBNP|194672‏
996 ‎‡2 BLBNB|001554655‏
996 ‎‡2 ISNI|0000000115789284‏
996 ‎‡2 PTBNP|950350‏
996 ‎‡2 BLBNB|000577034‏
996 ‎‡2 LC|no2019165890‏
996 ‎‡2 LC|n 81036211‏
996 ‎‡2 BLBNB|000191701‏
996 ‎‡2 NUKAT|n 2010104628‏
996 ‎‡2 ISNI|0000000070318525‏
996 ‎‡2 ISNI|0000000066410556‏
996 ‎‡2 PTBNP|1567912‏
996 ‎‡2 LC|no 96061982‏
996 ‎‡2 ISNI|0000000499317277‏
996 ‎‡2 ISNI|0000000120144624‏
996 ‎‡2 BNF|17827672‏
996 ‎‡2 PTBNP|928291‏
996 ‎‡2 PTBNP|1796961‏
996 ‎‡2 CAOONL|ncf11266198‏
996 ‎‡2 PTBNP|1487704‏
996 ‎‡2 LC|n 87802045‏
996 ‎‡2 BLBNB|000322378‏
996 ‎‡2 LC|n 2023255078‏
996 ‎‡2 SUDOC|169778223‏
996 ‎‡2 PTBNP|215304‏
996 ‎‡2 SUDOC|245427619‏
996 ‎‡2 DNB|130226408‏
996 ‎‡2 DNB|137802846‏
996 ‎‡2 PTBNP|190431‏
996 ‎‡2 DNB|1227997256‏
996 ‎‡2 LC|no2018066081‏
996 ‎‡2 BLBNB|000322395‏
996 ‎‡2 PTBNP|1158736‏
996 ‎‡2 SUDOC|140045201‏
996 ‎‡2 PTBNP|1457197‏
996 ‎‡2 BLBNB|000322394‏
996 ‎‡2 LC|n 78092820‏
996 ‎‡2 PTBNP|1713050‏
996 ‎‡2 BLBNB|001458538‏
996 ‎‡2 BNF|16670818‏
996 ‎‡2 ISNI|0000000112402531‏
996 ‎‡2 PTBNP|172778‏
996 ‎‡2 ISNI|0000000048375638‏
996 ‎‡2 BLBNB|001535325‏
996 ‎‡2 NUKAT|n 2008049592‏
996 ‎‡2 DNB|1271929651‏
996 ‎‡2 LC|n 84151110‏
996 ‎‡2 PTBNP|1673824‏
996 ‎‡2 ISNI|0000000069319328‏
996 ‎‡2 PTBNP|155621‏
996 ‎‡2 DNB|1077204256‏
996 ‎‡2 ISNI|0000000068703782‏
996 ‎‡2 ISNI|0000000112433629‏
996 ‎‡2 BLBNB|000176757‏
996 ‎‡2 BLBNB|000424365‏
996 ‎‡2 ISNI|0000000067815440‏
996 ‎‡2 BLBNB|000167678‏
996 ‎‡2 PTBNP|35617‏
996 ‎‡2 BIBSYS|90608214‏
996 ‎‡2 PTBNP|1044242‏
996 ‎‡2 ISNI|0000000070723141‏
996 ‎‡2 BLBNB|000308714‏
996 ‎‡2 PTBNP|1224069‏
996 ‎‡2 PTBNP|205766‏
996 ‎‡2 SUDOC|123696577‏
996 ‎‡2 PTBNP|135443‏
996 ‎‡2 RERO|A003695707‏
996 ‎‡2 PTBNP|1464711‏
996 ‎‡2 ISNI|0000000069788167‏
996 ‎‡2 ISNI|0000000030976443‏
996 ‎‡2 ISNI|0000000024958142‏
996 ‎‡2 ISNI|0000000068406833‏
996 ‎‡2 DNB|1316247759‏
996 ‎‡2 ISNI|0000000069223721‏
996 ‎‡2 ISNI|0000000044471614‏
996 ‎‡2 SUDOC|098028618‏
996 ‎‡2 BNF|14619118‏
996 ‎‡2 BLBNB|000343247‏
996 ‎‡2 PTBNP|252060‏
996 ‎‡2 PTBNP|1434153‏
996 ‎‡2 DNB|1027539998‏
996 ‎‡2 ISNI|0000000069510464‏
996 ‎‡2 ISNI|0000000079998264‏
996 ‎‡2 PTBNP|1471128‏
996 ‎‡2 PTBNP|217653‏
996 ‎‡2 BLBNB|000988860‏
996 ‎‡2 PTBNP|130224‏
996 ‎‡2 BLBNB|000495784‏
996 ‎‡2 SUDOC|276707184‏
996 ‎‡2 ISNI|0000000069308864‏
996 ‎‡2 PTBNP|1859965‏
996 ‎‡2 PTBNP|38473‏
996 ‎‡2 CAOONL|ncf10313424‏
996 ‎‡2 PTBNP|1179930‏
996 ‎‡2 ISNI|0000000069722977‏
996 ‎‡2 DNB|1302428195‏
996 ‎‡2 RERO|A009355106‏
996 ‎‡2 ISNI|0000000079894537‏
996 ‎‡2 ISNI|0000000078748108‏
996 ‎‡2 RERO|A011631941‏
996 ‎‡2 ISNI|0000000041510075‏
996 ‎‡2 PTBNP|257777‏
996 ‎‡2 BLBNB|000483064‏
996 ‎‡2 ISNI|0000000068608136‏
996 ‎‡2 PLWABN|9812829563505606‏
996 ‎‡2 ISNI|0000000068117265‏
996 ‎‡2 PTBNP|231306‏
996 ‎‡2 PTBNP|1377695‏
996 ‎‡2 BLBNB|001465621‏
996 ‎‡2 DNB|1056281839‏
996 ‎‡2 RERO|A014223370‏
996 ‎‡2 ISNI|0000000067810084‏
996 ‎‡2 DNB|1057530808‏
996 ‎‡2 PTBNP|1581852‏
996 ‎‡2 ISNI|0000000069007869‏
996 ‎‡2 ISNI|0000000025352943‏
996 ‎‡2 BLBNB|000405136‏
996 ‎‡2 LC|n 2015210069‏
996 ‎‡2 BLBNB|000322392‏
996 ‎‡2 LC|no2017058744‏
996 ‎‡2 ISNI|0000000039003840‏
996 ‎‡2 ISNI|0000000068202662‏
996 ‎‡2 DNB|112304693X‏
996 ‎‡2 NTA|099983044‏
996 ‎‡2 ISNI|0000000070436214‏
996 ‎‡2 BNF|12402291‏
996 ‎‡2 ISNI|0000000123452374‏
996 ‎‡2 PTBNP|794683‏
996 ‎‡2 BLBNB|000455369‏
996 ‎‡2 ISNI|0000000070437102‏
996 ‎‡2 LC|n 89183083‏
996 ‎‡2 BLBNB|000188073‏
996 ‎‡2 PTBNP|1839900‏
996 ‎‡2 BNE|XX1134967‏
996 ‎‡2 PTBNP|1906725‏
996 ‎‡2 ISNI|0000000047746003‏
996 ‎‡2 J9U|987007267586605171‏
996 ‎‡2 PTBNP|1308938‏
996 ‎‡2 ISNI|0000000048741722‏
996 ‎‡2 BLBNB|000209138‏
996 ‎‡2 PTBNP|1280208‏
996 ‎‡2 PTBNP|1326723‏
996 ‎‡2 ISNI|0000000068287133‏
996 ‎‡2 BNF|15102730‏
996 ‎‡2 ISNI|000000002125289X‏
996 ‎‡2 ISNI|0000000069916835‏
996 ‎‡2 DNB|1074947312‏
996 ‎‡2 ISNI|0000000069797274‏
996 ‎‡2 PTBNP|1447569‏
996 ‎‡2 LC|n 2008215500‏
996 ‎‡2 PTBNP|1368176‏
996 ‎‡2 ISNI|0000000428212072‏
996 ‎‡2 LC|n 2011205975‏
996 ‎‡2 ISNI|0000000069616875‏
996 ‎‡2 LC|n 2021059600‏
996 ‎‡2 PTBNP|1590067‏
996 ‎‡2 BNF|14598155‏
996 ‎‡2 BLBNB|000322380‏
996 ‎‡2 PTBNP|239212‏
996 ‎‡2 LC|no2005015350‏
996 ‎‡2 ISNI|0000000047668789‏
996 ‎‡2 PTBNP|1868780‏
996 ‎‡2 RERO|A024161048‏
996 ‎‡2 LC|n 2004024370‏
996 ‎‡2 PTBNP|149118‏
996 ‎‡2 LC|n 2006041686‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏